Bone Biologics Cash And Equivalents vs. Net Asset

BBLGW Stock  USD 27.80  0.69  2.42%   
Based on Bone Biologics' profitability indicators, Bone Biologics Corp may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Bone Biologics' ability to earn profits and add value for shareholders. At this time, Bone Biologics' Debt To Assets are fairly stable compared to the past year. Price Book Value Ratio is likely to climb to 0.43 in 2024, whereas Operating Cash Flow Per Share is likely to drop (38.13) in 2024.
For Bone Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bone Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bone Biologics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bone Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bone Biologics Corp over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.14)
Return On Assets
(0.57)
Return On Equity
(1.19)
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bone Biologics Corp Net Asset vs. Cash And Equivalents Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bone Biologics's current stock value. Our valuation model uses many indicators to compare Bone Biologics value to that of its competitors to determine the firm's financial worth.
Bone Biologics Corp is rated below average in cash and equivalents category among its peers. It is rated fifth in net asset category among its peers making up about  841.84  of Net Asset per Cash And Equivalents. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bone Biologics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Bone Net Asset vs. Cash And Equivalents

Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Bone Biologics

Cash

 = 

Bank Deposits

+

Liquidities

 = 
4.44 K
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Bone Biologics

Net Asset

 = 

Current Market Value

-

Current Liabilities

 = 
3.74 M
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.

Bone Net Asset Comparison

Bone Biologics is currently under evaluation in net asset category among its peers.

Bone Biologics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bone Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bone Biologics will eventually generate negative long term returns. The profitability progress is the general direction of Bone Biologics' change in net profit over the period of time. It can combine multiple indicators of Bone Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income(410.55)(431.08)
Operating Income-9.4 M-9 M
Income Before Tax-8.9 M-8.5 M
Net Loss-8.9 M-8.5 M
Total Other Income Expense Net479.6 K503.6 K
Income Tax Expense-2 M-1.9 M
Net Interest Income-730.2 K-766.7 K
Net Loss-6.5 M-6.8 M
Interest Income1.9 KK
Net Loss(34.01)(35.71)
Income Quality 1.07  0.70 
Net Loss(0.54)(0.51)

Bone Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bone Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bone Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bone Biologics' important profitability drivers and their relationship over time.

Use Bone Biologics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bone Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bone Biologics will appreciate offsetting losses from the drop in the long position's value.

Bone Biologics Pair Trading

Bone Biologics Corp Pair Trading Analysis

The ability to find closely correlated positions to Bone Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bone Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bone Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bone Biologics Corp to buy it.
The correlation of Bone Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bone Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bone Biologics Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bone Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bone Biologics position

In addition to having Bone Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Health Management Thematic Idea Now

Health Management
Health Management Theme
Major hospitals and healthcare providers. The Health Management theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.